

Clonal Concordance and Genomic Heterogeneity in Single CTC Copy Number Alterations vs. Paired IMPACT Metastatic Tissue Sequencing from mCRPC Patient Samples



Howard I. Scher¹, Angel Rodriguez², Jerry Lee², Ramsay Sutton², Ryon P. Graf², Nicole Schreiber¹, Melanie Hullings¹, Yipeng Wang², Mark Landers², David Solit¹, Michael Berger¹, Nikolaus Schultz¹, Ryan Dittamore²


¹Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY ² Epic Sciences, Inc. San Diego, CA

Memorial Sloan Kettering Cancer Center

Background

High CTC phenotypic heterogeneity is associated with non-response to ARSi but not taxane chemotherapy assessed using a non-invasive rapid blood test. The MSK-IMPACT™ NGS assay is FDA approved for tumor tissue profiling to guide treatment selection. The frequency of directly actionable alterations in prostate cancer (PC) is ~35%. Recognizing many cancers harbor intra-, inter-, and intercellular heterogeneity we sought to evaluate concordance of sequencing single CTCs vs. paired biopsy analyzed by MSK-IMPACT, to assess CTC clonality in circulation vs. tumor, the relationship to CTC phenotypic heterogeneity and response.

Methods



CK, CD45, & AR; 4) CTC identification based on (DAPI+; CK+; CD45-) phenotype using a multi-parametric digital pathology algorithm.

Genomics Processing & Methodology Single cell dual index/barcoded 5) WHOLE GENOME SEQUENCING & BIOINFORMATICS


Single CTC Sequencing:

1-3) Identified CTCs were relocated, and CTCs were individually isolated. 4-5) Each recovered cell was lysed, whole genome amplified (WGA), shotgun dual index NGS-library prepared and low pass whole genome sequenced using Illumina NextSeq 500. CNV analysis was perform as previously described.


MSK-IMPACT™ Sequencing:

DNA derived from matched fresh biopsy was sequenced as previously described by the MSK-IMPACT tumor sequencing. For purposes of comparison, CNV were called from across the panel using the same CNV pipeline used for single cells.


Patient Demographics & Study Design




CTC and Matched Tissue Demonstrate Concordant and Discordant Genomic Profiles **Example 2: Dissimilar Clonal Genomic Profile Example 1: Similar Clonal Genomic Profile**




Prevalence of Multiple Unique Genomic Clones Observed in CTCs




High Clonal Concordance in Bone/Visceral; Low Concordance with LN Metastatic




High Occurrence of Resistant Genomics Identified in CTCs



Genomic Alterations Identified in CTCs & Tissue **Associate with Survival**



Case Study: CTC Genomic Profile in Aggressive Disease



Conclusions

- Single CTC sequencing is often concordant to metastatic tissue, but unique CTC clones highlight the prevalence of sub-clonal disease in mCRPC patients under-sampled by tissue biopsy.
- Lymph node biopsy may under-represent the cancer cells circulating in the blood, leading to lower utility of genomic calls in these patients.
- Known genomic alterations of progressive mCRPC are frequently observed in CTCs from patients with short OS

Funding: Equal distributions of funds from NIH/NCI P50-CA92629 SPORE in Prostate Cancer Research Program (PC121111 and PC131984), Prostate Cancer Foundation Challenge Award, and David H. Koch Fund for Prostate Cancer Research were used to support the design and conduct of the study at Memorial Sloan Kettering Cancer Center.

Reference: Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. Greene SB, Dago AE, et al., PLoS One. 2016 Nov 16;11(11):e0165089.